132 related articles for article (PubMed ID: 10523799)
41. Hypophosphorylation of topoisomerase IIalpha in etoposide (VP-16)-resistant human carcinoma cell lines associated with carboxy-terminal truncation.
Matsumoto Y; Takano H; Kunishio K; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Jul; 92(7):799-805. PubMed ID: 11473732
[TBL] [Abstract][Full Text] [Related]
42. Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage.
Gieseler F; Bauer E; Nuessler V; Clark M; Valsamas S
Leukemia; 1999 Nov; 13(11):1859-63. PubMed ID: 10557063
[TBL] [Abstract][Full Text] [Related]
43. Catalytic inhibition of human DNA topoisomerase IIalpha by hypericin, a naphthodianthrone from St. John's wort (Hypericum perforatum).
Peebles KA; Baker RK; Kurz EU; Schneider BJ; Kroll DJ
Biochem Pharmacol; 2001 Oct; 62(8):1059-70. PubMed ID: 11597574
[TBL] [Abstract][Full Text] [Related]
44. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia.
Willmore E; de Caux S; Sunter NJ; Tilby MJ; Jackson GH; Austin CA; Durkacz BW
Blood; 2004 Jun; 103(12):4659-65. PubMed ID: 15010369
[TBL] [Abstract][Full Text] [Related]
45. Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells.
Ritke MK; Roberts D; Allan WP; Raymond J; Bergoltz VV; Yalowich JC
Br J Cancer; 1994 Apr; 69(4):687-97. PubMed ID: 8142256
[TBL] [Abstract][Full Text] [Related]
46. Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity.
Stacey DW; Hitomi M; Chen G
Mol Cell Biol; 2000 Dec; 20(24):9127-37. PubMed ID: 11094065
[TBL] [Abstract][Full Text] [Related]
47. Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance than is daunorubicin.
Fukushima T; Inoue H; Takemura H; Kishi S; Yamauchi T; Inai K; Nakayama T; Imamura S; Urasaki Y; Nakamura T; Ueda T
Leuk Res; 1998 Jul; 22(7):625-9. PubMed ID: 9680113
[TBL] [Abstract][Full Text] [Related]
48. Selenite induces topoisomerase I and II-DNA complexes in K562 leukemia cells.
López-Lázaro M; Willmore E; Elliott SL; Austin CA
Int J Cancer; 2008 Nov; 123(9):2217-21. PubMed ID: 18712718
[TBL] [Abstract][Full Text] [Related]
49. Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint.
Kozuki T; Chikamori K; Surleac MD; Micluta MA; Petrescu AJ; Norris EJ; Elson P; Hoeltge GA; Grabowski DR; Porter ACG; Ganapathi RN; Ganapathi MK
Nucleic Acids Res; 2017 Jun; 45(10):5995-6010. PubMed ID: 28472494
[TBL] [Abstract][Full Text] [Related]
50. Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors.
van der Zee AG; de Jong S; Keith WN; Hollema H; Boonstra H; de Vries EG
Cancer Res; 1994 Feb; 54(3):749-55. PubMed ID: 8306337
[TBL] [Abstract][Full Text] [Related]
51. Etoposide-induced DNA strand breaks in relation to p-glycoprotein and topoisomerase II protein expression in leukaemic cells from patients with AML and CLL.
Zhou R; Vitols S; Gruber A; Liliemark J; Wang Y; Liliemark E
Br J Haematol; 1999 May; 105(2):420-7. PubMed ID: 10233413
[TBL] [Abstract][Full Text] [Related]
52. Altered expression and activity of topoisomerases during all-trans retinoic acid-induced differentiation of HL-60 cells.
Aoyama M; Grabowski DR; Isaacs RJ; Krivacic KA; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
Blood; 1998 Oct; 92(8):2863-70. PubMed ID: 9763571
[TBL] [Abstract][Full Text] [Related]
53. The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines.
Kurz EU; Wilson SE; Leader KB; Sampey BP; Allan WP; Yalowich JC; Kroll DJ
Mol Cancer Ther; 2001 Dec; 1(2):121-31. PubMed ID: 12467229
[TBL] [Abstract][Full Text] [Related]
54. Down-regulation of topoisomerase IIalpha in CEM cells selected for merbarone resistance is associated with reduced expression of Sp3.
Mo YY; Wang Q; Beck WT
Cancer Res; 1997 Nov; 57(22):5004-8. PubMed ID: 9371492
[TBL] [Abstract][Full Text] [Related]
55. Enhanced topoisomerase I activity and increased topoisomerase II alpha content in cisplatin-resistant cancer cell lines.
Minagawa Y; Kigawa J; Irie T; Kanamori Y; Itamochi H; Cheng X; Terakawa N
Jpn J Cancer Res; 1997 Dec; 88(12):1218-23. PubMed ID: 9473741
[TBL] [Abstract][Full Text] [Related]
56. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia.
Kaufmann SH; Karp JE; Jones RJ; Miller CB; Schneider E; Zwelling LA; Cowan K; Wendel K; Burke PJ
Blood; 1994 Jan; 83(2):517-30. PubMed ID: 7904487
[TBL] [Abstract][Full Text] [Related]
57. 2-[4-(7-chloro-2-quinoxalinyloxyphenoxy]-propionic acid (XK469), an inhibitor of topoisomerase (Topo) IIbeta, up-regulates Topo IIalpha and enhances Topo IIalpha-mediated cytotoxicity.
Mensah-Osman EJ; Al-Katib AM; Wu HY; Osman NI; Mohammad RM
Mol Cancer Ther; 2002 Dec; 1(14):1321-6. PubMed ID: 12516965
[TBL] [Abstract][Full Text] [Related]
58. Topoisomerase II activities in AML and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines.
Gieseler F; Glasmacher A; Kämpfe D; Wandt H; Nuessler V; Valsamas S; Kunze J; Wilms K
Leukemia; 1996 Jul; 10(7):1177-80. PubMed ID: 8683999
[TBL] [Abstract][Full Text] [Related]
59. DNA topoisomerase IIalpha and -beta expression in human ovarian cancer.
Withoff S; van der Zee AG; de Jong S; Hollema H; Smit EF; Mulder NH; de Vries EG
Br J Cancer; 1999 Feb; 79(5-6):748-53. PubMed ID: 10070864
[TBL] [Abstract][Full Text] [Related]
60. Altered drug sensitivity in response to idarubicin treatment in K562 human leukaemia cells.
Locke VL; Davey RA; Davey MW
Br J Haematol; 1999 Jul; 106(1):86-91. PubMed ID: 10444167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
